Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
4.95B | 4.99B | 5.06B | 5.20B | 5.80B | 5.54B | Gross Profit |
3.83B | 3.89B | 3.87B | 4.03B | 4.56B | 4.39B | EBIT |
449.60M | 385.90M | 356.40M | 545.20M | 734.10M | 640.60M | EBITDA |
560.40M | 509.10M | 482.20M | 672.70M | 854.60M | 740.90M | Net Income Common Stockholders |
280.40M | 254.30M | 142.20M | 321.30M | 447.20M | 372.60M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
329.40M | 415.30M | 575.20M | 508.00M | 601.50M | 1.05B | Total Assets |
2.68B | 2.73B | 2.81B | 2.73B | 2.82B | 3.08B | Total Debt |
2.40B | 2.47B | 2.77B | 2.88B | 2.96B | 2.64B | Net Debt |
2.07B | 2.05B | 2.19B | 2.38B | 2.36B | 1.59B | Total Liabilities |
3.42B | 3.53B | 3.87B | 4.00B | 4.21B | 3.93B | Stockholders Equity |
-736.00M | -801.10M | -1.06B | -1.27B | -1.39B | -856.10M |
Cash Flow | Free Cash Flow | ||||
164.40M | 163.40M | 222.50M | 196.10M | 308.90M | 516.60M | Operating Cash Flow |
271.80M | 285.40M | 357.50M | 352.50M | 460.30M | 628.60M | Investing Cash Flow |
-70.60M | -84.60M | -134.80M | -156.20M | -156.40M | -123.20M | Financing Cash Flow |
-249.30M | -335.30M | -148.30M | -264.70M | -728.60M | -320.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $985.55M | 15.36 | 21.57% | ― | 25.92% | ― | |
73 Outperform | $560.00M | 16.47 | 6.78% | ― | -2.69% | -43.24% | |
68 Neutral | $1.27B | ― | -7.25% | ― | 5.94% | -115.82% | |
64 Neutral | $889.20M | 45.59 | 5.40% | 0.40% | 3.36% | 7.51% | |
62 Neutral | $705.80M | 2.52 | -31.74% | ― | -2.45% | 100.59% | |
59 Neutral | $904.51M | ― | -34.65% | ― | 252.64% | 85.10% | |
52 Neutral | $5.19B | 3.04 | -44.64% | 2.82% | 16.45% | -0.53% |
Herbalife reported its financial results for the first quarter of 2025, with net sales reaching $1.2 billion, down 3.4% from the previous year, but showing a 1.4% increase on a constant currency basis. The company exceeded its guidance for adjusted EBITDA and improved its gross profit margin. Recent strategic acquisitions, including Pro2col Health LLC and Pruvit Ventures, are expected to enhance Herbalife’s product offerings and market reach. The company also revised its full-year guidance, narrowing its net sales range and raising its adjusted EBITDA expectations.
Spark’s Take on HLF Stock
According to Spark, TipRanks’ AI Analyst, HLF is a Neutral.
Herbalife’s overall stock score is 47, reflecting significant financial challenges with declining revenues and high leverage. While there are positive developments in leadership and earnings guidance, technical indicators and regional sales declines suggest caution. The stock appears undervalued, offering potential upside if strategic initiatives succeed, but risks remain substantial.
To see Spark’s full report on HLF stock, click here.